Related Experiment Videos
New antiretroviral drugs
1Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, New York 10024, USA. rgulick@med.cornell.edu
Summary
New antiretroviral drugs are crucial for treating HIV, especially for resistant strains. Research is ongoing for novel reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, and integrase inhibitors to improve HIV treatment.
Area of Science:
- Virology
- Pharmacology
- Infectious Diseases
Background:
- Current combination antiretroviral therapy for HIV presents challenges.
- There is a need for novel antiretroviral drugs to enhance convenience, reduce toxicity, and overcome viral resistance.
Purpose of the Study:
- To review the development of new antiretroviral drugs for HIV treatment.
- To highlight investigational drugs targeting different mechanisms of action.
Main Methods:
- Review of investigational antiretroviral drugs in development.
- Categorization of drugs by their mechanism of action (reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, integrase inhibitors).
Main Results:
- Several novel nucleoside analog reverse transcriptase inhibitors (e.g., emtricitabine, amdoxovir), non-nucleoside reverse transcriptase inhibitors (e.g., DPC 083, TMC 125), and protease inhibitors (e.g., atazanavir, tipranavir, TMC 114) are under investigation.
- New classes of drugs, including HIV entry inhibitors (e.g., PRO 542, Schering C, enfuvirtide, T-1249) and HIV integrase inhibitors (e.g., S-1360), are also being explored.
Conclusions:
- Continued progress in HIV treatment relies on the development of new antiretroviral drugs with novel properties and mechanisms of action.
- Investigational drugs offer promise in addressing challenges associated with current HIV therapies, including drug resistance.